Schön Klinik Hamburg Eilbek


Hospital

Location:
Hamburg, Germany


Publications in cooperation with FAU scientists


Kavanaugh, A., Gladman, D.D., Gomez-Reino, J.J., Hall, S., Lespessailles, E., Mease, P.J.,... Wollenhaupt, J. (2018). Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis. (pp. AB114-AB114).
Gladman, D.D., Kavanaugh, A., Gomez-Reino, J.J., Wollenhaupt, J., Cutolo, M., Schett, G.,... Mease, P.J. (2018). LONG-TERM (156-WEEK) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS WITH APREMILAST INPSORIATIC ARTHRITIS SUBJECTS: ANALYSIS OF A LARGE, POOLED PALACE 1-3 DATABASE.
Gladman, D.D., Kavanaugh, A., Gómez-Reino, J.J., Wollenhaupt, J., Cutolo, M., Schett, G.,... Mease, P.J. (2018). Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open, 4(1). https://dx.doi.org/10.1136/rmdopen-2018-000669
Gladman, D.D., Kavanaugh, A., Gomez-Reino, J.J., Wollenhaupt, J., Cutolo, M., Schett, G.,... Mease, P.J. (2017). APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM. (pp. 942-942).
Mease, P.J., Gladman, D.D., Gomez-Reino, J.J., Hall, S., Kavanaugh, A., Lespessailles, E.,... Wollenhaupt, J. (2017). Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies.
Kavanaugh, A., Gladman, D.D., Gomez-Reino, J.J., Hall, S., Lespessailles, E., Mease, P.J.,... Wollenhaupt, J. (2017). DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL. (pp. 936-937).
Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L.,... Krieg, T. (2017). European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology, 31(9), 1401-1424. https://dx.doi.org/10.1111/jdv.14458
Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L.,... Krieg, T. (2017). European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 31(10), 1581-1594. https://dx.doi.org/10.1111/jdv.14466
Gladman, D.D., Kavanaugh, A., Adebajo, A.O., Gomez-Reino, J.J., Wollenhaupt, J., Cutolo, M.,... Mease, P.J. (2016). APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS. (pp. 33-34).
Gladman, D., Kavanaugh, A., Adebajo, A., Gomez-Reino, J., Wollenhaupt, J., Cutolo, M.,... Mease, P. (2016). Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials. (pp. 1169-1169).
Gladman, D.D., Kavanaugh, A., Gomez-Reino, J.J., Wollenhaupt, J., Cutolo, M., Schett, G.,... Mease, P.J. (2016). Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials.
Gossec, L., Smolen, J.S., Ramiro, S., De Wit, M., Cutolo, M., Dougados, M.,... Van Der Heijde, D. (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 75(3), 499-510. https://dx.doi.org/10.1136/annrheumdis-2015-208337
Mease, P.J., Gladman, D.D., Gomez-Reino, J.J., Hall, S., Kavanaugh, A., Lespessailles, E.,... Wollenhaupt, J. (2016). Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials.
Kavanaugh, A., Mease, P.J., Gomez-Reino, J.J., Adebajo, A.O., Wollenhaupt, J., Gladman, D.D.,... Schett, G. (2014). Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Annals of the Rheumatic Diseases, 73(6), 1020-6. https://dx.doi.org/10.1136/annrheumdis-2013-205056

Last updated on 2016-28-11 at 12:47